Comprehensively Covering Multiple Myeloma: IASO Bio’s GPRC5D CAR-T Product RD118 Receives IND Approval from NMPA

NANJING, China, SHANGHAI and SAN JOSE, Calif., June 28, 2024 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, today announces that the…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks